Moreover, the expression of SREBP-1 and its gene transactivation activity were strongly triggered by glucose and FFAs, highlighting the involvement of this lipogenic transcription factor in the regulation of the pathway of DNL in the NAFLD model. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.